Invetx Announces Completion of $25.5 Million Series A Financing and Key Appointments to Executive Team

New Investors Include Casdin Capital and Tekla Capital

Antibody Development Experts Bill Brondyk, PhD, Named Chief Scientific Officer and Colin Giles, PhD, Chief Development Officer

Invetx, a pioneer in protein-based therapeutics for animal health, announced today that it has raised an additional $10.25 million in its Series A financing, bringing the total amount to $25.5 million. New investors include Casdin Capital and funds managed by Tekla Capital Management, LLC, joining existing lead investor Anterra Capital, as well as strategic investors AbCellera Biologics and WuXi Biologics. In addition, Invetx announced the appointments of Bill Brondyk, PhD, as chief scientific officer and Colin Giles, PhD, as chief development officer to its executive team.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930005118/en/

Bill Brondyk, PhD, Named Chief Scientific Officer at Invetx (Photo: Business Wire)

“We are pleased to complete our $25.5 million Series A financing, welcoming blue-chip life science investors

Read More